Nordea Investment Management AB Sells 80,186 Shares of DENTSPLY SIRONA Inc. $XRAY

Nordea Investment Management AB cut its holdings in shares of DENTSPLY SIRONA Inc. (NASDAQ:XRAY) by 14.1% in the fourth quarter, Holdings Channel reports. The institutional investor owned 490,280 shares of the medical instruments supplier’s stock after selling 80,186 shares during the quarter. Nordea Investment Management AB’s holdings in DENTSPLY SIRONA were worth $5,604,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds also recently modified their holdings of the company. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. acquired a new stake in shares of DENTSPLY SIRONA in the first quarter worth $26,000. Huntington National Bank raised its stake in DENTSPLY SIRONA by 292.9% during the 3rd quarter. Huntington National Bank now owns 2,786 shares of the medical instruments supplier’s stock valued at $35,000 after purchasing an additional 2,077 shares during the last quarter. Caitong International Asset Management Co. Ltd raised its stake in DENTSPLY SIRONA by 337.9% during the 3rd quarter. Caitong International Asset Management Co. Ltd now owns 2,750 shares of the medical instruments supplier’s stock valued at $35,000 after purchasing an additional 2,122 shares during the last quarter. True Wealth Design LLC boosted its holdings in DENTSPLY SIRONA by 49.7% in the 3rd quarter. True Wealth Design LLC now owns 3,557 shares of the medical instruments supplier’s stock valued at $45,000 after purchasing an additional 1,181 shares during the period. Finally, Central Pacific Bank Trust Division grew its position in DENTSPLY SIRONA by 100.0% in the 3rd quarter. Central Pacific Bank Trust Division now owns 4,000 shares of the medical instruments supplier’s stock worth $51,000 after purchasing an additional 2,000 shares during the last quarter. 95.70% of the stock is owned by institutional investors.

Insider Transactions at DENTSPLY SIRONA

In other DENTSPLY SIRONA news, Director James D. Forbes purchased 5,000 shares of the business’s stock in a transaction on Monday, March 9th. The stock was purchased at an average price of $12.48 per share, for a total transaction of $62,400.00. Following the completion of the purchase, the director directly owned 10,000 shares in the company, valued at approximately $124,800. This trade represents a 100.00% increase in their ownership of the stock. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Gregory T. Lucier acquired 27,555 shares of the firm’s stock in a transaction on Monday, March 2nd. The shares were bought at an average cost of $14.24 per share, for a total transaction of $392,383.20. Following the completion of the acquisition, the director directly owned 27,555 shares of the company’s stock, valued at approximately $392,383.20. This represents a ∞ increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. In the last 90 days, insiders have acquired 70,000 shares of company stock valued at $956,437. Corporate insiders own 0.50% of the company’s stock.

Analysts Set New Price Targets

Several research firms have recently issued reports on XRAY. Weiss Ratings restated a “sell (d-)” rating on shares of DENTSPLY SIRONA in a report on Wednesday, January 21st. Robert W. Baird increased their target price on shares of DENTSPLY SIRONA from $12.00 to $14.00 and gave the company a “neutral” rating in a research note on Friday, February 27th. Mizuho lifted their target price on DENTSPLY SIRONA from $14.00 to $16.00 and gave the stock a “neutral” rating in a research report on Monday, March 2nd. Bank of America upgraded DENTSPLY SIRONA from a “neutral” rating to a “buy” rating and boosted their price target for the company from $13.00 to $17.00 in a research note on Thursday, February 19th. Finally, UBS Group reduced their price objective on DENTSPLY SIRONA from $17.00 to $16.00 and set a “buy” rating for the company in a research report on Tuesday, February 3rd. Three research analysts have rated the stock with a Buy rating, ten have assigned a Hold rating and two have assigned a Sell rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Hold” and an average target price of $14.42.

DENTSPLY SIRONA Trading Down 0.2%

Shares of DENTSPLY SIRONA stock opened at $11.66 on Friday. DENTSPLY SIRONA Inc. has a 52-week low of $9.85 and a 52-week high of $17.18. The firm has a market capitalization of $2.33 billion, a PE ratio of -3.89, a price-to-earnings-growth ratio of 1.37 and a beta of 0.97. The company has a debt-to-equity ratio of 1.50, a current ratio of 1.51 and a quick ratio of 1.03. The company’s fifty day moving average price is $12.58 and its two-hundred day moving average price is $12.24.

DENTSPLY SIRONA (NASDAQ:XRAY) last released its quarterly earnings data on Thursday, February 26th. The medical instruments supplier reported $0.27 EPS for the quarter, missing analysts’ consensus estimates of $0.28 by ($0.01). DENTSPLY SIRONA had a positive return on equity of 18.85% and a negative net margin of 16.25%.The business had revenue of $961.00 million for the quarter, compared to the consensus estimate of $926.40 million. During the same period in the previous year, the business posted $0.26 earnings per share. DENTSPLY SIRONA’s revenue was up 6.2% on a year-over-year basis. DENTSPLY SIRONA has set its FY 2026 guidance at 1.400-1.500 EPS. On average, analysts expect that DENTSPLY SIRONA Inc. will post 1.84 EPS for the current year.

DENTSPLY SIRONA Profile

Dentsply Sirona Inc (NASDAQ: XRAY) is a leading global manufacturer of professional dental products and technologies. The company, formed through the merger of Dentsply International and Sirona Dental Systems in February 2016, brings together a long heritage of innovation in dental care. Headquartered in Charlotte, North Carolina, Dentsply Sirona develops and markets a comprehensive range of dental consumables, laboratory products, and advanced imaging and CAD/CAM systems.

The company’s product portfolio spans preventive, restorative, orthodontic, endodontic and surgical care.